The FDA has expanded the approval of Jascayd (nerandomilast), an oral phosphodiesterase 4 (PDE4) inhibitor, to include treatment of progressive pulmonary fibrosis in adults.
The Social Security Administration has requested the National Academies of Sciences, Engineering, and Medicine to review the latest published research and science and produce a report addressing best ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback